RoyGulickMD

PubMed

• Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV.
  Bisrat K Abraham, Mary Vogler, Achala Talati, Prapitha Suresh, Balwant Gill
  Journal of Acquired Immune Deficiency Syndromes. 2025-01-01
• Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial.
  Stanley E Cooper, Shuaiqi Zhang, Daniel Haines, Kenneth H Mayer, K Rivet Amico
  AIDS and Behavior. 2024-11-01
• Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates.
  Jeremy Sugarman, Brian W Weir, Chen Dun, Roy M Gulick, Timothy J Wilkin
  AIDS Care. 2024-08-01

Journal Articles

• Combination Therapy with Anti-HIV-1 Antibodies Maintains Viral Suppression  
  Michael S Seaman, Katrina Millard, Marina Caskey, Michel C Nussenzweig, Roy M Gulick, Thiago Y Oliveira, Nature
• Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals  
  Roy M Gulick, Thiago Y Oliveira, Marina Caskey, Michel C Nussenzweig, Michael S Seaman, Katrina Millard, Nature
• The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
  Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
• 5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients  
  Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR, JAIDS, 1/1/2014
• Modeling immunologic endpoints as a function of time of switch to second-line ART with incomplete data on switching times  
  Johnson BA, Ribaudo H, Gulick RM, Eron JJ, Biometrics, 1/1/2013
• Invasive meningococcal disease in men who have sex with men  
  Simon MS, Weiss D, Gulick RM, Ann Intern Med, 1/1/2013
• Racial differences in response to antiretroviral therapy for HIV infection: an AIDS Clinical Trials Group (ACTG) study analysis  
  Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM, Clin Infect Dis, 1/1/2013
• Regulatory T cells and the risk of CMV end-organ disease in AIDS patients  
  Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Collier AC, Behm T, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson M, JAIDS, 1/1/2013
• HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug  
  Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, J Virol, 1/1/2012
• Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development  
  Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, HIV Clin Trials, 1/1/2012
• Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists  
  Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Antimicrob Agents Chemother, 1/1/2012
• Novel clinical trials designs for the development of new antiretroviral agents  
  Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, AIDS, 1/1/2012
• Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures  
  Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, J Virol, 1/1/2012
• Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti  
  Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, J Intern AIDS Soc, 1/1/2012
• A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256  
  Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR, J Infect Dis, 1/1/2012
• Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095  
  Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, J Am Stat Assoc, 1/1/2012
• Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants  
  Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Pharmacogenet Genomics, 1/1/2012
• CCR5 antagonism in HIV infection: Current concepts and future opportunities  
  Wilkin TJ, Gulick RM, Ann Rev Med, 1/1/2012
• Next-generation oral preexposure prophlaxis: beyond tenofovir  
  Abraham BK, Gulick R, Curr Opin HIV AIDS, 1/1/2012
• Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in A...  
  Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD, Pac Symp Biocomput, 1/1/2011
• Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure  
  Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes D, Stevenson M, PLoS Pathogens, 1/1/2011
• Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity  
  Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E, Clin Infect Dis, 1/1/2011
• Change in high-sensitivity C-reactive protein (hsCRP) levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals  
  Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ, AIDS Res Hum Retroviruses, 1/1/2011
• Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study  
  Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chene G, D'Ar..., J Acquir Immune Defic Syndr, 1/1/2011
• Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases  
  Haas DW, Kuritzkes D, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich ..., HIV Clin Trials, 1/1/2011
• Join now to see all